Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cipla Forms $30 Million China Respiratory Drug JV with Jiangsu Acebright

publication date: Jul 17, 2019

India's Cipla formed a $30 million joint venture with Jiangsu Acebright Pharma to bring Cipla's generic drugs to the China market. Cipla will contribute 80% of the JV's capital and own 80% of the JV, which will also establish a manufacturing facility for Cipla's respiratory products in China. Cipla, which is active in many global markets, is India's third largest pharma. One month ago, in a similar India-China agreement, Sun Pharma of India forged a deal with China Medical System Holdings to develop and commercialize two drugs in Greater China. More details....

Stock Symbol: (BSE: 500087)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital